Perflubutane
As of the edition of 20 October 2026, Perflubutane is a small molecule: marketed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed
- Kind
- Small molecule
- Brand name
- Sonazoid
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- GE Healthcare
- Registered trials
- 21, 2 stopped early
- Disease areas
- Cancer; Digestive system; Heart and blood vessels; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 0 | 0 |
| Phase 1 | 6 | 4 | 0 | 1 |
| Phase 2 | 5 | 3 | 1 | 0 |
| Phase 3 | 6 | 2 | 2 | 1 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 21 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Acusphere | Lead sponsor of trials | 2004 to now |
| GE Healthcare | Lead sponsor of trials | 2014 to now |